Nanostring Tech Cmn (NASDAQ:NSTG) shares traded on -27.84% below secure line and closed at $11.3. Leerink Swann maintained the shares of NSTG in report on Wednesday, August 5 with "Buy" rating. Several studies suggest that positive earnings surprises not only lead to an immediate hike in a stock's price, but also to a gradual increase over time. Zacks Investment Research upgraded NanoString Technologies from a "hold" rating to a "buy" rating and set a $19.00 price target on the stock in a report on Wednesday, July 5th. Finally, BidaskClub lowered NanoString Technologies from a "sell" rating to a "strong sell" rating in a report on Friday, July 28th. Cowen & Co initiated the stock with "Outperform" rating in Wednesday, September 30 report. Redmile Group Llc sold 67,605 shares as Nanostring Technologies Inc (NSTG)'s stock declined 7.69%.
Recently, In a note shared with investors on Thursday, 12 October, NanoString Technologies (NASDAQ:NSTG) shares have had their Outperform Rating reiterated by analysts at Baird, who now has a $19 price target on firm.
Nanostring Tech Cmn (NASDAQ:NSTG) has average revenue estimates of $26.71 Million, compared to low analyst estimates of $26 Million and high estimates of $28 Million for the current quarter. Blackrock invested 0% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG). 575,120 shares of the company traded hands. NanoString Technologies has a 12-month low of $9.56 and a 12-month high of $23.45.
NSTG's 20 days and 50 days MA (moving average) comparison clear the blur picture. Shares are now up over the past year, outperforming the broad market by -100% and underperformed a peer group of similar companies by -384%.
NanoString Technologies (NASDAQ:NSTG) last issued its earnings results on Tuesday, August 8th. Next quarter's EPS is estimated at $-0.56 with next year's EPS anticipated to be $-2.40. The return on equity ratio or ROE stands at -329.6 percent while most common profitability ratio return on investment (ROI) was -69.1 percent.
In the last earnings report the EPS was $-2.12 and is projected to be $-2.17 for the current year with 25,204,000 shares now outstanding. The value of the total investment in NanoString Technologies, Inc. decreased from $796,000 to $156,000 a change of $640,000 quarter over quarter. "(NSTG) Lowered to "Neutral" at Janney Montgomery Scott" was originally published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this piece on another site, it was illegally stolen and reposted in violation of global copyright and trademark law. The stock of NanoString Technologies Inc (NASDAQ:NSTG) earned "Buy" rating by Janney Capital on Wednesday, March 16. Hedge funds and other institutional investors own 92.98% of the company's stock. California Public Employees Retirement System invested 0% in NanoString Technologies Inc (NASDAQ:NSTG). California State Teachers Retirement System now owns 31,367 shares of the biotechnology company's stock worth $519,000 after purchasing an additional 400 shares during the period. OxFORD Asset Management LLP raised its holdings in NanoString Technologies by 150.4% in the 2nd quarter. Bank of America Corp DE now owns 11,404 shares of the biotechnology company's stock worth $227,000 after acquiring an additional 1,627 shares during the last quarter. Retail Bank Of America Corporation De reported 0% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG). State Street Corp now owns 261,864 shares of the biotechnology company's stock valued at $4,332,000 after buying an additional 30,864 shares during the period. Manufacturers Life Ins Communications The reported 0% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG). The Manufacturers Life Insurance Company now owns 15,542 shares of the biotechnology company's stock valued at $257,000 after buying an additional 3,132 shares during the period. It improved, as 14 investors sold NSTG shares while 16 reduced holdings.
NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue.